[1]
|
J. Bell, “Amlexanox for the Treatment of Recurrent Aphthous Ulcers,” Clinical Drug Investigation, Vol. 25, No. 9, 2005, pp. 555-566.
doi:org/10.2165/00044011-200525090-00001
|
[2]
|
H. Makino, T. Saijo, Y. Ashida, H. Kuriki and Y. Maki, “Mechanism of Action of an Antiallergic Agent, Am- lexanox (AA-673), in Inhibiting Histamine Release from Mast Cells,” International Archives of Allergy and Immunology, Vol. 82, No. 1, 1987, pp. 66-71.
doi:org/10.1159/000234292
|
[3]
|
C. Scully and S. Porter, “Oral mucosal disease: Recurrent aphthous stomatitis,” British Journal of Oral and Maxil-lofacial Surgery, Vol. 46, No. 3, 2008, pp. 198-206.
doi:org/10.1016/j.bjoms.2007.07.201
|
[4]
|
J. Liu, X. Zeng, Q. Chen, Y. Cai, F. Chen , Y. Wang, H. Zhou, M. Lin, J. Shi, Z. Wang and Y. Zhang, “An Evaluation on the Efficacy and Safety of Amlexanox Oral Adhesive Tablets in the Treatment of Recurrent Minor Aphthous Ulceration in a Chinese Cohort: A Randomized, Double-Blind, Vehicle-Controlled, Unparallel
Multicenter Clinical Trial,” Oral Surgery Oral Medicine Oral Pa-Thologz Oral Radiology and Endodontology, Vol. 102, No. 4, 2006, pp. 475-481.
|
[5]
|
M. Sugiura, R. Hayakawa and T. Osada, “Fixed drug Eruption Due to Amlexanox,” Contact Dermatitis, Vol. 38, No. 2, 1998, pp. 65-67.
doi:org/10.1111/j.1600-0536.1998.tb05654.x
|
[6]
|
S. McComish, A. Mize, J. Harris, N. Premkumar and L. E. Colon, “A High-Pressure Liquid Chromatographic Method for Measuring Mitotane: [1,1-(o,p-Dichlorodiphenyl)-2,2- Dichloroethane] and Its Metabolite 1,1-(o,p'-Dichlorodi- phenyl)-2,2-dichloroethene in Plasma,” Therapeutic Drug Monitoring, Vol. 17, No. 5, 1995, pp. 526-531.
doi:org/10.1097/00007691-199510000-00015
|
[7]
|
T Shishibori, “Three Distinct Anti-Allergic Drugs, Am-lexanox, Cromolyn and Tranilast, Bind to S100A12 and S100A13 of the S100 Protein Family,” Biochemical Journal, Vol. 338, 1999, pp. 583-589.
|
[8]
|
A. Khandwala, R. G. V. Inwegen and M. C. Alfano, “5% Amlexanox Oral Paste, a New Treatment for Recurrent Minor Aphthous Ulcers: I. Clinical Demonstration of Acceleration of Healing and Resolution of Pain,” Oral Surgery Oral Medicine Oral Pathologz Oral Radiology and Endodontology, Vol. 83, No. 2, 1997, pp. 222- 230.
|
[9]
|
A. Khandwala, R. G. V. Inwegen, M. R. Charney and M. C. Alfano, “5% Amlexanox Oral Paste, a New Treatment for Recurrent Minor Aphthous Ulcers II: Pharmacokinetics
and Demonstration of Clinical Safety,” Oral Surgery Oral Medicine Oral Pathologz Oral Radiology and Endodon- tology, Vol. 83, No. 2, 1997, pp. 231-238.
|
[10]
|
J. Jacob, “Stable Viscous Liquid Formulations of Am-lexanox for the Prevention and Treatment of Mucosal Diseases and Disorders,” US Patent App. 09/971, 2001, p. 562.
|
[11]
|
USP, “United States pharmacopoeia,” 32nd Edition, United States Pharmacopeial Convention, Rockville, 2008.
|
[12]
|
International Federation of Pharmaceutical Manufactures & Associations, “ICH Stability Testing of New Drug Substances and Products Q1A (R2),” International Con-ference on Harmonization, Geneva, 2003.
|
[13]
|
M. Bakshi and S. Singh, “Development of Validated Stability-Indicating Assay Methods-Critical Review,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 28, No. 6, 2002, pp. 1011-1040.
doi:org/10.1016/S0731-7085(02)00047-X
|
[14]
|
U. S. Food and Drug Administration, “ICH Guidelines on Validation of Analytical Procedures: Text and Metho-dology Q2 (R1),” Federal Register, FDA, Silver Spring 2005.
|